Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

Many regret delaying hair loss treatments like finasteride and minoxidil, impacting self-esteem and dating. Additional treatments include scalp micropigmentation and hair transplants, with some experiencing side effects or high costs.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

A user shares their positive experience of embracing baldness, noting increased attractiveness and dating success after shaving their head. They encourage others to consider going bald instead of relying on medications like Minoxidil, finasteride, or RU58841.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The post and conversation discuss the effectiveness of pyrilutamide for hair loss, with comparisons to finasteride and RU58841. Users express skepticism due to failed trials and high costs, with some waiting for more data before trying pyrilutamide.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Finasteride and Dutasteride are effective treatments for hair loss, with Dutasteride being superior based on long-term data. Side effects are minimal, and concerns should not deter treatment.

The conversation is about someone's 2-month hair regrowth progress using topical minoxidil and finasteride combined with 0.5mm dermarolling, started 3 months ago. They did not provide a baseline picture from the start date.

People are not using RU58841 for hair loss because it's not FDA approved, lacks long-term safety data, and is difficult to obtain and verify. They prefer FDA-approved treatments like minoxidil, finasteride, ketoconazole shampoo, and microneedling.

People discussed their experiences with anti-androgens for hair loss, mentioning side effects like chest pains with RU58841 and skepticism due to lack of safety data, while considering Fluridil as a potential addition to treatment. Some users expressed reluctance to use these chemicals.

A 40-year-old used minoxidil, dutasteride, RU58841, and microneedling for one year, resulting in noticeable hair regrowth despite initial shedding. They believe having more hair is beneficial for dating at their age and also recommend staying fit, eating well, and sleeping over 8 hours.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The conversation discusses the use of dutasteride (DUT) versus finasteride (FIN) for hair loss treatment, with some users preferring DUT for its effectiveness while others choose FIN due to its approval status, better long-term data, and lower risk of side effects. Users share personal experiences with both medications, including side effects and effectiveness.

The conversation is about a 26-year-old man's hair regrowth progress after three months of taking oral Minoxidil and Finasteride. There was a mix-up with the photo dates provided for comparison.

The user had a hair transplant with 4500 grafts and has been using minoxidil twice daily for over a year but stopped finasteride due to severe side effects. The transplant cost $3500 and improved their self-confidence, positively affecting their dating life.

The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

User asks if Kintor, HMI-115, or Olix will release hair loss drugs in 2023. Conversation discusses potential treatments and release dates.

Hair loss treatments, including microneedling, minoxidil, finasteride and RU58841; the efficacy of these treatments; criticisms of Kevin Mann's content related to his selective data presentation and biases towards certain treatments; and other topics such as DHT being labeled a "trash hormone" and critiques of other hairloss YouTubers.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.

A user had a disappointing dermatologist appointment where they were denied prescriptions for Dutasteride and oral Minoxidil for hair loss and were only offered a hair transplant referral. Other users sympathized, discussed self-medication, and suggested consulting a transplant doctor for up-to-date treatments.